The Barostim neo System is an implantable neuromodulation device designed to improve cardiac function by delivering electrical stimulation to baroreceptors in the wall of the carotid artery. The system is designed to take advantage of the body’s natural baroreflex system. Activation of baroreceptors in the wall of the carotid artery with baroreflex activation therapy stimulat…
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Rozlytrek (Entrectinib)
Rozlytrek (entrectinib) is an oral tumor-agnostic agent intended to selectively inhibit the tyrosine kinase activity of TRKA, TRKB, TRKC, and ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase) rearrangements. Rozlytrek is indicated for the treatment of adult and adolescent patients whose cancers have NTRK (neurotrophic tyrosine receptor kinase) gene fusion, and for whom the…
Balversa (Erdafitinib) for Urothelial Carcinoma
Balversa is an oral kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations and has progressed during or following at least 1 line of prior platinum-containin…
Rozlytrek (Entrectinib)
Rozlytrek (entrectinib) is an oral tumor-agnostic agent intended to selectively inhibit the tyrosine kinase activity of TRKA, TRKB, TRKC, and ROS1 (ROS proto-oncogene 1 receptor tyrosine kinase) rearrangements. Rozlytrek is indicated for the treatment of adult and adolescent patients whose cancers have NTRK (neurotrophic tyrosine receptor kinase) gene fusion, and for whom the…
Balversa (Erdafitinib) for Urothelial Carcinoma
Balversa is an oral kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations and has progressed during or following at least 1 line of prior platinum-containin…
Sunosi (Solriamfetol)
Sunosi is an oral phenylalanine-derived selective dopamine and norepinephrine reuptake inhibitor (DNRI). Norepinephrine inhibits rapid eye movement sleep and promotes wakefulness. Dopamine plays a role in areas of the brain responsible for sleep regulation. Sunosi is indicated for the improvement in wakefulness in adult patients with excessive sleepiness associated with narco…
Sunosi (Solriamfetol)
Sunosi is an oral phenylalanine-derived selective dopamine and norepinephrine reuptake inhibitor (DNRI). Norepinephrine inhibits rapid eye movement sleep and promotes wakefulness. Dopamine plays a role in areas of the brain responsible for sleep regulation. Sunosi is indicated for the improvement in wakefulness in adult patients with excessive sleepiness associated with narco…
Turalio (Pexidartinib) for Tenosynovial Giant Cell Tumor
Turalio (pexidartinib) is an oral small molecule kinase inhibitor of colony stimulating factor-1 receptor (CSF1R) for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and which is not amenable to improvement with surgery.
Turalio (Pexidartinib) for Tenosynovial Giant Cell Tumor
Turalio (pexidartinib) is an oral small molecule kinase inhibitor of colony stimulating factor-1 receptor (CSF1R) for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and which is not amenable to improvement with surgery.
Nubeqa (Darolutamide) for Nonmestastatic CRPC
Nubeqa is a nonsteroidal second-generation androgen receptor inhibitor that competes with androgen by binding to the androgen receptor. It reduces the ability of androgen to promote the growth of prostate cancer cells. Nubeqa is indicated for the treatment of patients with nonmetastatic castration-resistant prostate cancer.